WO2008140200A1 - Compositions externes pour la peau - Google Patents

Compositions externes pour la peau Download PDF

Info

Publication number
WO2008140200A1
WO2008140200A1 PCT/KR2008/002510 KR2008002510W WO2008140200A1 WO 2008140200 A1 WO2008140200 A1 WO 2008140200A1 KR 2008002510 W KR2008002510 W KR 2008002510W WO 2008140200 A1 WO2008140200 A1 WO 2008140200A1
Authority
WO
WIPO (PCT)
Prior art keywords
skin
weight
parts
composition
skin according
Prior art date
Application number
PCT/KR2008/002510
Other languages
English (en)
Inventor
Seon-Il Kim
Original Assignee
Seon-Il Kim
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seon-Il Kim filed Critical Seon-Il Kim
Publication of WO2008140200A1 publication Critical patent/WO2008140200A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/23—Sulfur; Selenium; Tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/26—Aluminium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/345—Alcohols containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A61K2800/522—Antioxidants; Radical scavengers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A61K2800/524—Preservatives

Definitions

  • the present invention relates to an external composition for skin containing sulfur and alum, which can be used as cosmetic or dermatological compositions to improve and treat various skin diseases.
  • the present invention promptly improves skin damage and pruritus resulting from eczema, atopic dermatitis, tinea, pustulosis palmaris et plantaris, or wounds, without involving toxicity or side effects.
  • the present invention has the effect of healing without leaving scars, and also has effects of skin-whitening and reducing and preventing wrinkles.
  • Cosmetics are used for the purpose of protecting skin, preventing skin diseases, and enhancing the wearer's appearance and cleaning. However, some ingredients that are undesirable in light of the above purposes are included as necessary components of cosmetic formulations and thereby cause skin diseases.
  • Atopic dermatitis commonly known as eczema
  • eczema is an eczema-like dermatological disorder found with atopic people. i
  • the cause of atopic dermatitis is still unknown, but it seems to be related to a genetic factor.
  • a dominant theory is that the disease is a kind of autoimmune diseases.
  • Atopic dermatitis has distinctive symptoms and signs, which differentiates it from other common types of eczema and dermatitis. The disease accounts for 70—80% of infant eczema and recently has been frequently found in adults as well.
  • antibiotics such as erythromycin or estrogen to decrease the production of sebum have been widely used, but they are associated with some side effects.
  • Cosmetics for acne treatment have included substances such as vitamin A derivatives, benzoyl peroxide, silisic acid, and triclosan, however, while these substances have produced some degree of anti-microbial effects, they have been associated with side effects including rubefaction and oversensitivity or photosensitivity of skin.
  • An object of the present invention is to provide external compositions for curing or relieving skin diseases, with the purpose of solving the problems as noted above, which strongly prohibit the generation of cyclooxygenase-2 and free radicals, involves no toxicity or side effects, promotes the renewal of normal skin while leaving no scars, reduces formation of wrinkles, and possesses a good moisturizing effect.
  • Another object of the present invention is to provide external compositions for curing or relieving skin diseases, and which provide supportive functions for the treatment of skin diseases and functions requested for skin health such as enhancement of inflammation healing and cell revitalization, disinfection, relief of pruritus, prevention and relief of wrinkles, provision of long- lasting moisture, and maintenance and promotion of skin elasticity.
  • Another object of the present invention is to provide an external composition for curing or relieving skin diseases, where the skin diseases to be treated by the composition can be dermal inflammations, acne, xerosis, tinea pedis, eczema, allergic rushes, pruritus, tinea, psoriasis, pustulosis palmaris et plantaris, or atopic diseases.
  • Another object of the present invention is to provide an anti-microbial composition.
  • the present invention provides a pharmaceutical or cosmetic composition for curing or relieving skin diseases, which includes sulfur and alum.
  • the cosmetic composition for relieving skin diseases exerts a function of ameliorating damaged skin and the effect of skin rejuvenation in a manner explained below.
  • the ingredients of the composition according to the present invention penetrate into the cells in a damaged part and surrounding areas and disrupt bacterial membranes formed as a result of bacterial infection. Then the ingredients kill the bacteria. While maintaining the bactericidal process around the infected cells, the ingredients participate in the process of cell revitalization and promote blood circulation and physiological activities. They are engaged as intermediary substances in complicated reactions between the cells and substrates around the cells. In order for the damaged skin to recover, necessary nutrition has to be provided for the formation of cells and tissues in the damaged area. By promoting the formation of blood vessels, the ingredients enable rapid renewal of the skin.
  • the ingredients of the composition according to the present invention remove calluses that are thickly formed on the skin as a result of skin diseases. Once the calluses are removed, effective ingredients are able to deeply penetrate into the cells in the damaged area, where the effective ingredients remove pain and itch by eliminating poisonous products generated by the bacteria and show the effects of reducing wrinkles and moisturizing dry skin.
  • a cosmetic composition for curing or relieving skin diseases By using a cosmetic composition for curing or relieving skin diseases according to the present invention, one can expect the effect of restoring to normal damaged skin caused by psoriasis, blistery tinea, various types of eczema, itch, shingles, chronic pruritus, pustulosis palmaris et plantaris, fungal tinea pedis, and malignant intumescence, as well as the effects of whitening, prevention and relief of wrinkles, moisturizing, and callus removal.
  • the external composition for skin according to the present invention a method of making the same, and functions of the same.
  • the external composition for skin according to the present invention includes sulfur and alum.
  • the composition includes 0.001-5.0 parts by weight of sulfur and 0.5-8.0 part by weight of alum per 100 parts by weight of a carrier.
  • Alum can be provided in a form dissolved in water, tree sap, or deep ocean water.
  • the tree sap can be obtained from a living tree belonging to the group consisting of Bambusoideae, Aceraceae, Actinidiaceae, Elaeagnaceae, Alnus japonica, and Betulaceae.
  • Alum has effects of healing furuncles and wounds, and of removing moisture and oils.
  • burnt alum and fresh alum can be used, alone or in combination.
  • the sulfate to be used for the prevent invention can be manufactured in a form included in an alkaline aqueous solution. It is preferred that the sulfate is dissolved in an alkali metal solution or a solution prepared with ignited shell powders from the outer shells of snail, abalone, shellfish, and waste coral
  • Phellodendron amurensis extract extractable from the bark of
  • Phellodendron amurensis includes berberine, which has anti-rotting and antibacterial properties without allowing gram-positive, gram-negative bacteria and Neisseria gonorrhoeae to obtain resistance to the anti-infectant.
  • At least one antibiotic to be included in the composition can be selected from the group consisting of aminoglycoside, tetracycline, penicillins, cephalosporin, microrides, polypeptide, lincosamide, sulfon amide, and fluoroquinolone antibiotics.
  • the external composition for skin further includes at least one selected from the group of 0.5 to 8.0 parts by weight of cholesterol, 0.1 to 3.0 parts by weight of gypsum, 0.3 to 3.0 parts by weight of talc, and 0.5 to 5.0 parts by weight of pearl powder, per 100 parts by weight of a carrier.
  • Pearl powder is water-soluble and rich in minerals and bioactive substances. It has functions of maintaining low acidity and moisture on skin, enhancing immunity of skin, improving blood flow, and encouraging cell rejuvenation.
  • Gypsum helps in discharging unnecessary water out of the body at the damaged skin area, thereby drying mucosa resulting from deceases such as eczema and cooling the heat. No harm, toxicity, or side effects of gypsum are known. Potassium hydroxide has the capability of disrupting protective membranes for bacteria formed with secretions around the damaged skin, and is used as a cleanser in removing impurities and as a disinfectant.
  • Cholesterol has ability of quickly coagulating impurities of mucosa, as gypsum does, and acts on damaged blood present in peripheral arteries, thereby allowing agents working on the extravagated blood to be engaged in the process of purifying the blood.
  • the external composition for skin can further include at least one ingredient selected from the group consisting of plant extracts, seaweeds extracts, animal extracts, minerals or extracts thereof, chemicals or general- purpose regenerative chemicals made of those chemicals, anti-bacterial agents, germicidal agents, moisturizing substances, nutrients, wrinkle-relieving substances, pruritus-relieving substances, anodyne, harmonic substances, blood circulation-improving agents, and anti-allergic substances.
  • a plant extract can be included at 0.1 - 30 parts by weight per 100 parts by weight of a carrier.
  • the plant extract can be a solvent extract extracted using at least one solvent selected from the group consisting of water, an alkali solution, and a C1-C4 alcohol.
  • the plant extract can be a plant oil.
  • plant extracts or plant oils can be at least one selected from the group consisting of bluet, Sasa Vetchii, Lonicera japonica, horsetail, Stellaria medium, comfrey, persimmon leaves, rice bran, mulberry tree, cocoon, branch, Thladiantha dubia, hardy (trifoliate) orange, apricot, peach leaves, Benicasa hispida, pomegranate, Cupressaceae, Lespedeza bicolor, Maximowiczia chinensis, Plantago asiatica, Ligularia fischeri, Opuntia, Taraxacum mongolicum Hand-mazz, Scutellaria baicalensis G, Selaginella Tamariscina, Schizonepeta tenuifolia.
  • composition according to the present invention can further include at least one anti-inflammatory agent selected from the group consisting of flufenamic acid, ibuprofen, benzydamin, indomethacin, prednisolone (steroid), and dexamethasone, the anti-inflammatory being included at 0.0001-2.0 parts by weight in 100 parts by weight of a carrier.
  • at least one anti-inflammatory agent selected from the group consisting of flufenamic acid, ibuprofen, benzydamin, indomethacin, prednisolone (steroid), and dexamethasone, the anti-inflammatory being included at 0.0001-2.0 parts by weight in 100 parts by weight of a carrier.
  • composition according to the present invention can further include at least one antibiotic selected from the group consisting of Aminoglycosides, Glycopeptides, Tetracyclines, Spectinomyxin, Bacitracin, Polymyxin, and Fosfomyxin, the anti-antibiotics being included at 0.0001-2.0 parts by weight with respect to 100 parts by weight of a carrier.
  • the composition according to the present invention can further include at least one extract obtained from the group consisting of earthworms, frogs, lizards, snakes, centipedes, ants, animal skin, animal's internal organs, and animal placentae.
  • seaweeds examples include brown seaweed, kelp, corals, and Salicornia herbacea.
  • Seaweed extracts that can be used for the present invention include carrageenan, alginic acid, sodium alginate, and potassium alginate, which are obtainable by purification of seaweed materials. One can use conventional purification methods to obtain those seaweed extracts.
  • Examples of minerals that can be used for the present invention are mica, gold, calcium, silicic acid, yellow soil, and sea soil.
  • Alum is dissolved in water, tree sap, plant extract, or deep sea water to prepare a solution.
  • Sulfur is prepared in a form dissolved in an alkaline aqueous solution.
  • the alkaline aqueous solution used to prepare the sulfur solution can be an alkali metal solution or can be obtained from ignited shell powder of snail, abalone, shellfish, and coral.
  • the above porous carrier can be zeolite, or can be prepared from shells of snail, abalone, shellfish, and coral.
  • the shells are heated to a high temperature, cooled, and finally crushed to powder.
  • an alkaline aqueous solution can be obtained.
  • Shell powder possesses strong alkaline properties, and most of its kinds include calcium.
  • a strong alkaline aqueous solution prepared from shell powder which retains oxygen in a large amount, provides oxygen to the cells in the damaged skin area, and engages, as an antioxidant, in the normalization process of the autoimmune condition, revitalizes cells, and relives symptoms of pruritus.
  • the shell powder causes no pain or harm and has no toxicity while being a strong antimicrobial material. It is capable of liquefying silver and sulfur.
  • Solvents can be used to manufacture the external composition for skin according to the present invention. Examples of the solvents are water, tree sap, and deep sea water.
  • the external compositions for skin according to the present invention can be pharmaceutical compositions.
  • the compositions of the present invention generally include pharmacologically acceptable carriers.
  • carriers to be used for topical application which is useful for the practice of the present invention, include - but are not limited to - alkylene glycol, and a mixture of alkylene glycol and at least one derivative of hydroxyalkyl cellulose.
  • compositions according to the present invention can be formulated and then administered in forms appropriate for drug delivery.
  • the compositions can be easily administered in various forms (direct topical application, application of patch for transdermal delivery, etc.)
  • the amount of dose administered can be determined depending on the condition of the disease to be treated.
  • the external compositions for skin according to the present invention can be cosmetic compositions, which can be provided in the form of skin gel, cream, lotion, powder, foundation, essence, gel, foam cleanser, soap, cleansing oil, powdery foundation, suspension foundation, or wax foundation.
  • Effective ingredients to be included in the external compositions for skin according to the present invention can be conventionally-used substances for cosmetics, in addition to the above-explained extracts.
  • the external compositions for skin according to the present invention can further include at least one additive selected from the group consisting of vitamins, amino acids, proteins, surfactants, emulsifiers, stabilizers, thickening agents, preservatives, moisturizers, anti-oxidants, perfumes, and pigments.
  • other conventional cosmetic ingredients can be further included, in addition to the above necessary ingredients.
  • Other additives without being restricted to the above-cited materials, can be included in the external compositions for skin according to the present invention.
  • compositions for skin For providing embodiments of the compositions for skin according to the present invention, methods for manufacturing three kinds of compositions are detailed below.
  • 0.15g of sulfur was dissolved in 5ml (5cc) of the above-prepared alkaline aqueous solution (ph12-13.5) or a potassium hydroxide solution, which is made by dissolving 0.3g of potassium hydroxide in 5ml of distilled water.
  • An alum solution was prepared by dissolving 0.5g of alum in 10ml of birch sap, collected from birch trees.
  • composition SBC Formation of composition SBC Subsequently, a base mixture including 2Og of general-purpose stearic acid, 2Og of glycerin, and 6Og of birch sap was placed in the heating chamber and stirred at a temperature below 70 "C for about 10 minutes. The resulting base mixture was injected into the vacuum chamber, in which the sulfur- and alum-absorbed material was placed, and was stirred and mixed under heat (below 70 0 C). The materials were cooled to obtain the composition SBC according to the present invention.
  • composition SBCO-1 in the present example includes pine resin, borax, camphor, silver, and Phellodendron amurensis as effective components, in addition to sulfur and alum contained in the above SBC.
  • composition SBCO-1 in the present example further includes cholesterol, pearl powder, talc, and gypsum as effective components, in addition to sulfur, alum, pine resin, borax, camphor, silver, and Phellodendron amurensis included in SBCO-1.
  • Example 1-1 vacuum-treated waste shell powder or zeolite was stirred and mixed together with 0.2g of cholesterol, 0.5g of pearl powder, 0.3g of talc, and 0.1g of gypsum, in addition to the sulfur solution and the alum solution, pine resin, borax, camphor, silver, and Phellodendron amurensis extract, to obtain the composition SBCO-2 according to the present invention.
  • RAW 264.7 cells were grown (Chi), to which lipopolysaccharides were added. 24 hrs after the addition, the activity of cyclooxygenase-2 was assayed by ELISA for prostaglandin E2, an arachidonic acid metabolite generated by cyclooxygenase-2. The amounts of prostaglandin E2 as quantified by ELISA are indicated in Table 1.
  • compositions according to the present invention inhibited the production of prostaglandin E2 at 25 ⁇ g/m. of administration dose, which involved no cytotoxic effects.
  • compositions according to the present invention directly inhibited cyclooxygenase-2 activity.
  • Table 2 shows that the composition of the present invention has excellent inhibiting effects with the activity of cyclooxygenase-2.
  • mice 35 hairless mice were provided. After cleansing their ears with alcohol, the ears' thickness was measured with a micrometer.
  • the 35 mice was divided into five groups of 7 mice, including two experimental groups (treated with 0.5% and 1.0% of the compositions of the present invention, respectively), one comparative group (treated with 1.0% indomethacin), and one control group (treated with arachidonic acid).
  • the respective materials were constantly applied to each group for four hours (once a day).
  • the compositions of the present invention were applied to the two experimental groups (20 ⁇ i of each of the compositions), with indomethacin applied to the comparative group (20 ⁇ i) and ethanol applied to the control group (20 ⁇ Jl).
  • Inhibition Rate (%) (A-B) / A x 100
  • Staphylococcus intermediusrbs known to cause atopic dermatis was used. This bacterial strain is the most commonly isolated strain from pyoderma, which causes both superficial and deep pyoderma. Thus it was used to assess the effects of the compositions according to the present invention on Staphylococcus, one of the manor pathogenic bacteria of skin diseases. Specifically the experiment was performed as shown in Table 4.
  • Bacterial strain used Staphylococcus intermediusrbs, which was isolated from eczematous corporis, a kind of atopic dermatis.
  • Negative Control 10ul of bacterial suspension added to 9.99ml of saline.
  • Escherichia coli which was isolated from the urine of a sick dog contracted with a urinary disease, was used for the experiment.
  • Negative Control 10ul of bacterial suspension added to 9.99ml of saline.
  • Staphylococcus aureus is known as one of pathogenic bacteria of atopic dermatitis.
  • ATCC American Type Culture Collection
  • 6538 of Staphylococcus aureus was used to assess the antibacterial effects on Staphylococcus aureus of the compositions according to the present invention. Based on the BHI
  • the amount of SBC used was 0.8g per 100ml of medium.
  • medium A and C in which SBC was contained, showed no bacterial growth until 27 hours had elapsed.
  • medium B in which neomycin was contained, bacterial growth rate was substantially suppressed for at least up to 12 hours, when compared to medium D, which used polymixin, or E, which merely used the basic BHI medium.
  • medium A which used SBCO-2, showed a more intensive effect of inhibition on the bacterial growth.
  • A SBC 0.8 g / 100 ml medium, plus1.85 g of trisodium phosphate
  • B Polymixin 0.8 g/100ml medium
  • C SBCO-2 0.8 g /100ml medium
  • D Neomycin 0.08g/100ml medium
  • E Medium control
  • Pathological materials including blister membranes, skin surface scales, and cellular tissues, were collected from the injured areas. Those materials were cut to 3-5mm specimens and were placed on slides. After a drop of 25 percent potassium hydroxide was added to each slide, a cover slip was placed thereon. After the specimen's keratinocytes were dissolved, microscopic examination was performed. It was confirmed that the infections were by tinea and mycosis. More specifically, microscopic findings were that the damage around the neck were atopic dermatitis and vesicular tinea caused by tinea and that the damage around the region from the chest to the back femoral region were a complication of infection by mycosis and generalized tinea.
  • Test Materials SBC, SBCO-1 , and SOCO-2 as manufactured according to the above examples of the present invention were used as test materials.
  • Control groups to be used for this experiment can be either the side of the left and right neck areas of the sick dog. The left side of the neck was chosen for this experiment. Among the five points where necroses occurred, the two points were chosen for the control group - lesions on the left side infected by tinea and mycos.
  • the left-side lesions and surrounding areas were sterilized with alcohol. Hairs around the lesions were removed, and alcohol was applied again. The animal was locally anesthetized with 2% lidocaine HCL. The lesions were cleansed with gauze and hydrogen peroxide. After the keratocytes facing the derma were removed, the lesions were sprayed with alcohol and air-dried. A mixture of SBC, SBCO- 1 , and SBCO-2 (with equal parts of each) was applied to the lesions. The lesions were then wrapped with the gauze. With a protective strap around the neck, the neck was protected from contact with the back legs. Meanwhile, the skin where the necroses occurred had 2-3mm of keratocytes.
  • the keratocytes were abrasively scrubbed with diamond paper until they get thin.
  • the scrubbed areas were then sprayed with alcohol and dried.
  • the SBC mixture was lightly patted over the lesions such that acting ingredients of the compositions could penetrate inside the skin. SBCO-2 was then applied again. The treatment was repeated three times a day.
  • a complex ointment was applied three times/day, and was made a mixture of teramycin ointment, neomycin ointment, variotin (a treatment for tinea), griseofulvin (antibiotic), a steroid ointment, an antihistamine ointment, centellasiatica to help rapid restoration of wounds, and elidel (immune-suppressive drug).
  • the two infection sites by mycosis were treated in an identical manner.
  • the lesion on the left side of the neck had stopped bleeding, and the dimension of the lesion was reduced to 6.8cm in length, 4.5cm in width, and 5mm in depth.
  • the areas infected with tinea and mycosis were colored light red.
  • the dimension of the lesion was decreased to 2.6cm in length, 2cm in width, and 2.6mm in depth, with no inflammation findings.
  • the experimental subject showed no behavior of scratching the damaged skin with the leg.
  • the color of the keratinocytes was turning white, and the centrifugal erythema was reduced in size.
  • compositions were found to engage in the immune system of skin, a possibility was also found to use the present invention for the treatments of intractable immune-related skin diseases, such as psoriasis and pustulosis palmaris et plantaris.
  • SBC ointments were applied to groups of patients, each group consisting of ten patients having the following diseases of atopic dermatitis, psoriasis, blistery tinea, various eczema, malignant acne, itching, shingles, psoriasis, chronic pruritus, palmoplanar pustulosis, or tinea pedis.
  • the applied skin areas were gently patted and massaged.
  • Application was performed at least two times a day, in the morning and afternoon, for 6 consecutive days. Among the patients treated, some degree of healing occurred in two patients, while almost complete healing occurred in the remaining 8 patients.
  • Application was made for three patients having initial atopic dermatitis, two times a day. As soon as the application and massage were performed, itching disappeared. From the time when 6 days passed after the first application, application was performed three times per a day, and two times per a day after 10 days had passed. In 60 days, no application was performed and complete healing was achieved.
  • the composition according to the present invention was applied to the patients and massaged into the skin, three to four times per a day for a week. In a week, the black-colored damaged skin turned red and was softened. Each of the patients treated experienced a full recovery and presented almost normalized skin.
  • compositions according to the present invention were applied to skin infected with psoriasis and blistery tinea and were massaged into the skin, for 180 days. The skin was completely rejuvenated.
  • compositions according to the present invention were applied to skin infected with allergic pruritus and were massaged into skin, for 12 days. As soon as the application was performed, itching was substantially improved. Pruritus completely disappeared in two months.
  • compositions according to the present invention were applied to the skin affected by contact dermatitis and massaged into the skin, three times/day. In 10 days, blisters and irritation disappeared.
  • compositions according to the present invention were applied two times/day. The skin was completely recovered in three days.
  • IC50 Inhibitory Concentration 50 (the concentration required for 50% cell kill)
  • IC50 values are 0.10 for SBCO-2, 0.11 for SBCO- 1 , and 0.13 for SCB, meaning that each of them showed 200 times lower levels of cytotoxicity than SLS and thus have excellent stability.
  • the compositions' cytotoxicity levels were similar to that of squalene, which has good stability.
  • Experiment 7-2 Acute or Chronic Toxicity Experiment a) Experiment Animal: rats of SPF SD line, female and male, aged 4 weeks. The rats, after being purchased, were housed in the laboratory for one week. Only animals that were healthy during one week of observation were used. Five females and five males were used. For the observation period, the animals were provided with solid food for lab animals and spring water. b) Method: SBC, SBCO-1 , and SBCO-2 manufactured according to the embodiments of the present invention were directly applied to the hair-removed skins. 10 hours after the application, the skins were rinsed and then dried before a re-application was made. The total duration given for the treatment was 30 days for each of the compositions of SBC 1 SBCO-1 , and SBCO-2. The method is further detailed in the following.
  • acetone-olive oil (4:1) was used as a delivery vehicle [reference: Kimber I (1990): Identification of contact allergens using the murine local lymph node assay, J. Appl. Toxicol. 10(3); 173 ⁇ 180].
  • a mixture was made of 2mg of the compositions of SBC, SBCO-1 , and SBCO-2 according to the present invention added to 10ml of a 0.5% alcohol solution. 50 ⁇ i of the mixture was applied to both ears of a mouse (Balb/c) for three days. Auricular lymph nodes were collected from the mouse and crushed to obtain single cells. The cells were cultured for 24 hours in the presence of the radiolabel [3H]thymidine, and cell proliferation was measured [cpm] as indicated in Table 12.
  • Table 12 shows that the compositions according to the present invention induce little allergic responses, as their S.l.s were below 3.
  • Test materials to be applied were prepared by mixing the composition SBCO-2 of the present invention with distilled water in concentrations shown in Table 13.
  • PII Primary cutaneous Irritation Index Table 13 indicates that the compositions of the present inventions are very safe to the extent that an intensive application (use of 80% concentration) caused little irritation to the skin.
  • test materials including the compositions of the present invention were as shown in Table 14. Firstly, a test material including a 1.0% mixture of the compositions of the present invention, 1.0% of sodium lauryl sulfate, and 10% of ethanol, secondly, a test material including 1.0% of sodium lauryl sulfate, and finally, a test material including 10% of ethanol were used.
  • test was conducted on 40 human subjects consisting of healthy males and females, following the guideline of CTFA (The Cosmetic, Toiletry, and Fragrance Association. Inc. Washington, D. C, 20036, 1991). 20 ml of test materials and solution was dripped in a Finn chamber and was placed on the back of a human subject. After 24 hours had elapsed, the patch was removed. Four hours after removal, the degree of irritation was determined according to the standard stated below. The results are shown in Table 14. ⁇ Standard for Determination>
  • Table 14 indicates that a 1.0% mixture of the compositions of the present invention greatly relieved the irritation caused by 1.0% of sodium lauryl sulfate or 10% of alcohol.
  • the result can be attributed to the excellent anti-inflammatory ability of the compositions of the present invention. That is, the results show that the compositions of the present invention are safe and are highly effective for anti-inflammation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Inorganic Chemistry (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Botany (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne une composition externe pour la peau contenant du soufre et de l'alun, qui peut être utilisée en tant que composition cosmétique ou composition dermatologique afin de soulager et de traiter diverses maladies cutanées. La présente invention permet de traiter rapidement les lésions cutanées et le prurit résultant de l'eczéma, de la dermatite atopique, de la teigne, de la pustulose palmaire et plantaire, ou les plaies, sans entraîner de toxicité ou d'effets secondaires. La présente invention permet la cicatrisation sans cicatrices, et permet également le blanchiment de la peau ainsi que la réduction et la prévention des rides.
PCT/KR2008/002510 2007-05-10 2008-05-02 Compositions externes pour la peau WO2008140200A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20070045375 2007-05-10
KR10-2007-0045375 2007-05-10
KR10-2007-0071689 2007-07-18
KR1020070071689A KR20070079596A (ko) 2007-05-10 2007-07-18 피부질환 치료 보조 기능성 화장료 조성물

Publications (1)

Publication Number Publication Date
WO2008140200A1 true WO2008140200A1 (fr) 2008-11-20

Family

ID=38600161

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2008/002510 WO2008140200A1 (fr) 2007-05-10 2008-05-02 Compositions externes pour la peau

Country Status (2)

Country Link
KR (2) KR20070079596A (fr)
WO (1) WO2008140200A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014071426A1 (fr) * 2012-11-06 2014-05-15 Gl & Partners Og Alun pour le traitement de maladies cutanées
GR1009068B (el) * 2016-05-09 2017-07-05 Πετρος Παναγιωτη Παναγιωτου Θεραπευτικο σκευασμα για πληγες κατακλισεων που, ψεκαζομενο επανω στην πληγη, δημιουργει επουλωτικη κρουστα - επιδεσμο
EP2358745B1 (fr) * 2008-10-29 2017-11-29 Leukolect As Leukolectines et leurs utilisations
WO2018064445A1 (fr) * 2016-09-30 2018-04-05 Eastern Technologies, Inc. Solution aqueuse à potentiel réducteur oxydatif, ses procédés de production et les procédés d'utilisation de celle-ci
CN108671059A (zh) * 2018-07-27 2018-10-19 遵义医学院 一种治疗灰指甲的药液及其制备方法
GB2561818A (en) * 2017-03-30 2018-10-31 Phyto Pharm Ltd Plant extract compositions
WO2019059766A1 (fr) 2017-09-21 2019-03-28 Rosaderma B.V. Formulation aqueuse pour le traitement topique d'affections cutanées

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200805017A2 (tr) * 2008-07-07 2008-11-21 Kazim Özgüven Yi̇ği̇t Cilt hastalıklarının tedavisi ve/veya önlenmesinde kullanılmak üzere dermatolojik kompozisyon
KR101720095B1 (ko) * 2009-10-30 2017-03-28 (주)아모레퍼시픽 천연식물추출물을 함유하는 여드름용 세안제 조성물
KR101219024B1 (ko) * 2010-06-14 2013-01-07 이인철 생약복합재 추출물을 유효성분으로 함유하는 화장료 조성물
KR101231864B1 (ko) * 2011-03-16 2013-02-08 이종호 해양심층수를 이용한 피부 염증 개선용 화장료 조성물
KR101355307B1 (ko) * 2011-09-15 2014-02-07 (주)제이에스향료 진범의 향취를 재현한 향료 조성물
KR101136464B1 (ko) * 2011-10-26 2012-04-19 이긍구 한약 추출물을 함유한 항균 조성물의 제조 방법
KR101867386B1 (ko) * 2012-03-23 2018-06-15 (주)아모레퍼시픽 천연 추출물을 포함하는 조성물
KR101505294B1 (ko) * 2013-06-19 2015-03-23 강릉원주대학교산학협력단 켈로이드 또는 흉터 형성을 감소시키기 위한 조성물
KR101387463B1 (ko) * 2013-08-09 2014-04-24 노희정 차전자피 팩제와 그 제조방법
KR101654409B1 (ko) * 2014-02-06 2016-09-09 대전대학교 산학협력단 항산화 및 항염증 효능이 있는 아토피 예방 또는 치료용 조성물
KR101498609B1 (ko) * 2014-04-18 2015-03-13 한방약초힐링 농업회사법인주식회사 한방약초농축액을 이용한 천연 한방 바디로션 제조방법 및 이를 이용하여 제조한 천연 한방 바디로션 조성물
KR101596576B1 (ko) * 2014-05-08 2016-02-22 김형길 화장료 조성물과 제조방법
KR101689267B1 (ko) * 2014-07-11 2016-12-23 원광대학교산학협력단 홍삼 추출물과 아스타잔틴의 혼합물을 유효성분으로 함유하는 주름 예방 또는 개선용 화장료 조성물
KR101685579B1 (ko) * 2015-08-12 2016-12-12 김수경 측백엽을 포함하는 천연유래물질을 이용한 피부 미백 화장료 조성물의 제조방법 및 이에 따라 제조된 피부 미백 화장료 조성물
KR102030021B1 (ko) * 2017-06-16 2019-10-08 박주영 마사지용 화장료 조성물
KR101947062B1 (ko) * 2017-10-31 2019-02-12 (주)아미드팩토리 복합 식물 추출물을 유효 성분으로 포함하는 화장료 조성물
KR102070347B1 (ko) * 2018-03-28 2020-01-28 김기현 명반을 포함하는 피부 소양증 개선용 조성물 제조 방법
KR102170412B1 (ko) * 2018-09-27 2020-10-27 (주)화니핀코리아 천연 복합추출물을 포함하는 마스크팩용 화장료 조성물
KR102170411B1 (ko) * 2018-09-27 2020-10-27 (주)화니핀코리아 미선나무 추출물을 포함하는 피부 광노화 개선 화장료 조성물
KR102160535B1 (ko) 2019-01-22 2020-09-28 이동완 오이, 가지 및 달팽이의 혼합 추출물을 유효성분으로 포함하는 탈모 방지 또는 발모 촉진용 조성물
KR102227874B1 (ko) * 2019-08-14 2021-03-19 주식회사 유렌코리아 아토피와 각종 피부염증을 개선할 수 있는 화장품조성물
KR102073009B1 (ko) 2019-10-14 2020-02-04 박목순 병풀 피토솜 및 상백피 추출물을 유효성분으로 포함하는 피부 염증 예방 또는 치료용 조성물
KR102104214B1 (ko) * 2019-12-24 2020-04-23 오한상 포타슘 알룸을 포함하는 화장료 조성물
KR102514125B1 (ko) 2020-09-24 2023-03-24 계명대학교 산학협력단 쇠별꽃 추출물을 유효성분으로 함유하는 백모 개선 또는 광 손상 보호용 조성물
WO2022154602A1 (fr) * 2021-01-15 2022-07-21 주식회사 피프틴디그리즈 Composition contenant un extrait de ligularia fischeri pour soulager les démangeaisons
KR102233709B1 (ko) * 2021-01-19 2021-03-29 김현숙 유황을 포함하는 화장료 조성물 및 이의 제조방법
KR102625331B1 (ko) * 2021-03-18 2024-01-18 주식회사 더말코리아 이온화 미네랄과 감잎 추출물 등 천연물로 조성된 천연 항균 탈취제 조성물
KR102531146B1 (ko) 2021-03-25 2023-05-11 경희대학교 산학협력단 물대(Arundo donax) 추출물을 포함하는 여드름 예방 또는 치료용 조성물
KR20230041639A (ko) 2021-09-17 2023-03-24 이용운 불순물이 적은 고백반, 이의 제조방법 및 이를 포함하는 미백기능성 화장료 조성물
KR102438804B1 (ko) * 2022-04-22 2022-09-01 주식회사 아트앤퍼퓸 주름 개선 및 피부 노화 방지를 위해 인삼 오일 및 프랑킨센스 오일을 이용하여 제조된 바디 로션 조성물 및 이의 제조 방법
KR102659309B1 (ko) * 2023-03-28 2024-05-03 주식회사 마노파레 아토피 피부염과 건조에 기인한 피부 가려움증 완화용 화장료 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1513476A (zh) * 2003-07-22 2004-07-21 马柏林 一种止痒、清根拔毒、消癣玉肤药物及其制备方法
CN1739719A (zh) * 2005-09-17 2006-03-01 郭丽萍 一种治疗皮肤病的中药制剂

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1513476A (zh) * 2003-07-22 2004-07-21 马柏林 一种止痒、清根拔毒、消癣玉肤药物及其制备方法
CN1739719A (zh) * 2005-09-17 2006-03-01 郭丽萍 一种治疗皮肤病的中药制剂

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2358745B1 (fr) * 2008-10-29 2017-11-29 Leukolect As Leukolectines et leurs utilisations
US10124034B2 (en) 2008-10-29 2018-11-13 Leukolect As Leukolectins and uses thereof
WO2014071426A1 (fr) * 2012-11-06 2014-05-15 Gl & Partners Og Alun pour le traitement de maladies cutanées
GR1009068B (el) * 2016-05-09 2017-07-05 Πετρος Παναγιωτη Παναγιωτου Θεραπευτικο σκευασμα για πληγες κατακλισεων που, ψεκαζομενο επανω στην πληγη, δημιουργει επουλωτικη κρουστα - επιδεσμο
WO2018064445A1 (fr) * 2016-09-30 2018-04-05 Eastern Technologies, Inc. Solution aqueuse à potentiel réducteur oxydatif, ses procédés de production et les procédés d'utilisation de celle-ci
US11357876B2 (en) 2016-09-30 2022-06-14 Eastern Technologies, Inc. Compositions and methods of making and using the same
GB2561818A (en) * 2017-03-30 2018-10-31 Phyto Pharm Ltd Plant extract compositions
GB2561818B (en) * 2017-03-30 2020-01-15 Phyto Sophos Ltd Plant extract compositions
WO2019059766A1 (fr) 2017-09-21 2019-03-28 Rosaderma B.V. Formulation aqueuse pour le traitement topique d'affections cutanées
NL2019602B1 (en) * 2017-09-21 2019-03-28 Rosaderma B V Aqueous formulation for the topical treatment of skin conditions
CN108671059A (zh) * 2018-07-27 2018-10-19 遵义医学院 一种治疗灰指甲的药液及其制备方法

Also Published As

Publication number Publication date
KR20100016450A (ko) 2010-02-12
KR20070079596A (ko) 2007-08-07

Similar Documents

Publication Publication Date Title
WO2008140200A1 (fr) Compositions externes pour la peau
KR100772575B1 (ko) 생약성분 추출물을 함유하는 피부 외용제 조성물
EP2278986B1 (fr) Produit pour une administration topique
RU2358750C2 (ru) Фармацевтические композиции на основе лишайника бородатого (usnea barbata) и зверобоя обыкновенного (hypericum perforatum) и их применение
KR20110131498A (ko) 패각 또는 패산호로부터 추출한 알카리용액에 은이온을 포함하는 항균제와 이를 포함하여 조성된 조성물.
HU229230B1 (hu) Gyógyászati készítmény Herpes simplex vírus és más fertõzések okozta megbetegedések kezelésére
KR101015702B1 (ko) 해조추출물을 포함하는 염증 및 피부자극 개선 및 완화용조성물
US10130652B2 (en) Anti-inflammatory compositions
KR20130015339A (ko) 여드름 치료용 크림 조성물
CA3061545A1 (fr) Composition pour soins de la peau
KR102300581B1 (ko) 식물추출물 또는 이의 분획물을 유효성분으로 함유하는 피부 상태 개선용 조성물
KR100668290B1 (ko) 아토피 피부의 개선 효과를 갖는 애기수영 및/또는 대황추출물 함유 화장료 조성물
KR102214985B1 (ko) 식물추출물 또는 이의 분획물을 유효성분으로 함유하는 피부 상태 개선용 조성물
JP2001081037A (ja) 化粧料組成物
KR100776755B1 (ko) 생약 추출물을 함유하는 가려움증 억제 및 완화용 조성물
KR102115668B1 (ko) 프로바이오틱스 발효물을 포함하는 항여드름 활성을 갖는 화장료 조성물
JPH0987188A (ja) 皮膚外用剤及び浴用剤
KR20110130184A (ko) 항 여드름 효능을 갖는 꾸지뽕나무 추출물과 이를 함유하는 화장료 조성물
WO2020232181A1 (fr) Compositions comprenant des extraits de plantes et des huiles et méthodes de traitement associées et leur préparation
KR20220104655A (ko) 나노화된 벌화분 추출물을 유효성분으로 포함하는 여드름 치료용 조성물
JP2003104886A (ja) 皮膚外用剤組成物
CN108619486B (zh) 一种治疗皮肤病的软膏剂及其制备方法
KR20170065187A (ko) 티트리 잎 복합 추출물을 함유하는 여드름 개선용 화장료 조성물
KR102488864B1 (ko) 가자 추출물 및 애엽 추출물을 함유하는 피부세균총의 생장 조절 또는 피부 면역 강화용 조성물
KR102650364B1 (ko) 석산(꽃무릇) 추출물을 유효성분으로 포함하는, 항산화, 항염증, 항아토피, 항주름 및 보습 증진용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08753307

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 20097023544

Country of ref document: KR

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08753307

Country of ref document: EP

Kind code of ref document: A1